NASDAQ: CMRAComera Life Sciences Holdings Inc Stock
$0.90+0.01 (+1.12%)
Updated Mar 29, 2023
CMRA Price
$0.90
Fair Value Price
$0.94
Market Cap
$19.98M
52 Week Low
$0.80
52 Week High
$15.30
P/E
-0.51x
P/B
-3.2x
P/S
20.31x
PEG
N/A
Dividend Yield
N/A
Revenue
$633.10k
Earnings
-$18.00M
Gross Margin
66.8%
Operating Margin
-2,840.57%
Profit Margin
-2,902.8%
Debt to Equity
-0.87
Operating Cash Flow
-$10M
Beta
-0.13
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
CMRA Overview
Comera Life Sciences Holdings, Inc., a preclinical stage life sciences company, develops an internal portfolio of proprietary therapeutics that incorporate its proprietary formulation platform, SQore. Its SQore platform is designed to enable the conversion of intravenous (IV) biologics to subcutaneous (SQ) versions. The company is advancing its primary product programs, CLS-001, a preclinical stage biobetter for Crohn's and Ulcerative Colitis disease, and CLS-002, a preclinical stage biobetter for various oncology indications. Comera Life Sciences Holdings, Inc. was founded in 2014 and is headquartered in Woburn, Massachusetts.
Zen Score
–
Industry Average (25)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how CMRA scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
CMRA ($0.90) is undervalued by 4.51% relative to our estimate of its Fair Value price of $0.94 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
CMRA ($0.90) is not significantly undervalued (4.51%) relative to our estimate of its Fair Value price of $0.94 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
CMRA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more CMRA due diligence checks available for Premium users.
Be the first to know about important CMRA news, forecast changes, insider trades & much more!
CMRA News
Valuation
CMRA fair value
Fair Value of CMRA stock based on Discounted Cash Flow (DCF)
Price
$0.90
Fair Value
$0.94
Undervalued by
4.08%
CMRA ($0.90) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
CMRA ($0.90) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
CMRA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
CMRA price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.51x
Industry
18.17x
Market
21.81x
CMRA price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-3.2x
Industry
4.92x
CMRA's financial health
Profit margin
Revenue
$156.1k
Net Income
-$3.0M
Profit Margin
-1,952.6%
CMRA's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
CMRA's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$3.7M
Liabilities
$5.5M
Debt to equity
-0.87
CMRA's short-term liabilities ($5.06M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
CMRA's short-term assets ($3.06M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
CMRA's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
CMRA's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$1.8M
Investing
$0.0
Financing
$1.1M
CMRA's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
CMRA vs Biotech Stocks
Comera Life Sciences Holdings Stock FAQ
©2023 WallStreetZen
Company
AboutBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.